Login / Signup

Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Giacomina MegaroEvelina MieleGian Paolo SpinelliIside AlessiGiada Del BaldoRaffaele CozzaIda RussoMaria Debora De PasqualeMaria Giuseppina CefaloPaolo TomàAndrea CaraiValentina Di RuscioMaria Antonietta De IorisAngela Mastronuzzi
Published in: Cancer reports (Hoboken, N.J.) (2022)
Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • mass spectrometry
  • high resolution
  • cerebrospinal fluid
  • high speed